cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Priveterra Acquisition Cor A
1 own
1 watching
Current Price
$11.03
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
339.82M
52-Week High
52-Week High
14.68000
52-Week Low
52-Week Low
6.81000
Average Volume
Average Volume
0
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization339.82M
icon52-Week High14.68000
icon52-Week Low6.81000
iconAverage Volume0
iconDividend Yield--
iconP/E Ratio--
What does the Priveterra Acquisition Cor A do?
Priveterra Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to acquire companies in the medical technology sector. The company was incorporated in 2020 and is based in Fort Lauderdale, Florida.
Read More
How much money does Priveterra Acquisition Cor A make?
News & Events about Priveterra Acquisition Cor A.
Globe Newswire
7 months ago
Financing represents minimum cash required to consummate the business combination and bridge AEON through key episodic migraine data readoutIRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) -- AEON...
Business Wire
1 year ago
AEON Biopharma, Inc. (AEON or the Company), a clinical-stage biopharmaceutical company developing a proprietary botulinum toxin for the treatment of multiple debilitating medical conditions, and Priveterra Acquisition Corp., (Nasdaq: PMGM) (Priveterra), a special purpose acquisition company, today...
Globe Newswire
1 year ago
Topline data expected to be announced in 2H 2023 Topline data from the Companys Phase 2 trial in preventive treatment of chronic migraine expected to be announced in 1H 2024 IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (AEON or the Company), a private clinical-stage ...
Globe Newswire
2years ago
ALISO VIEJO, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company, today announced the appointment of three new members to its Board of Directors effective as of the closing of the Companys initial public offering on August 3, 2021. The three appointments, ...
Frequently Asked Questions
Frequently Asked Questions
What is Priveterra Acquisition Cor A share price today?
plus_minus_icon
Can Indians buy Priveterra Acquisition Cor A shares?
plus_minus_icon
How can I buy Priveterra Acquisition Cor A shares from India?
plus_minus_icon
Can Fractional shares of Priveterra Acquisition Cor A be purchased?
plus_minus_icon
What are the documents required to start investing in Priveterra Acquisition Cor A stocks?
plus_minus_icon
What is today’s traded volume of Priveterra Acquisition Cor A?
plus_minus_icon
What is today’s market capitalisation of Priveterra Acquisition Cor A?
plus_minus_icon
What is the 52-Week High and Low Range of Priveterra Acquisition Cor A?
plus_minus_icon
What percentage is Priveterra Acquisition Cor A down from its 52-Week High?
plus_minus_icon
What percentage is Priveterra Acquisition Cor A up from its 52-Week Low?
plus_minus_icon
Current Price
$11.03
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00